Treatment of hepatic encephalopathy

New England Journal of Medicine

Volumn 337, Issue 7, 1997, Pages 473-479

  Riordan, Stephen M ^a   Williams, Roger ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE RECEPTOR; MANNITOL; PROSTACYCLIN;

CHRONIC LIVER DISEASE; ELECTROENCEPHALOGRAM; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HYPOTHESIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SHUNTING; TREATMENT PLANNING; UREA CYCLE;

AMINO ACIDS, BRANCHED-CHAIN; AMMONIA; ANTI-BACTERIAL AGENTS; DIAGNOSIS, DIFFERENTIAL; DIET, PROTEIN-RESTRICTED; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER TRANSPLANTATION; RECEPTORS, GABA-A;

EID: 0030879021     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199708143370707     Document Type: Review

References (73)

1. Gitlin N. Hepatic encephalopathy. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1996:605-17.
2. Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO Jr, McClain CJ. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980;140:519-21.
3. Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986;3:75-82.
4. Walton J. The neurology of some general (internal) medical disorders. In: Walton J, ed. Brain's diseases of the nervous system. 10th ed. Oxford, England: Oxford University Press, 1993:542-54.
5. Powell EE, Pender MP, Chalk JB, et al. Improvement in chronic hepatocerebral degeneration following liver transplantation. Gastroenterology 1990;98:1079-82.
6. Butterworth RF, Giguere JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987;6:1-12.
7. Mullen KD, Szauter KM, Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990;336:81-3.
8. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971;2:75-80.
9. Hu HL, Chen RD. Changes in free radicals, trace elements, and neurophysiological function in rats with liver damage induced by D-galactosamine. Biol Trace Elem Res 1992;34:19-25.
10. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084-92.
11. Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-4.
12. Ferenci P. Hepatic encephalopathy. In: McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. Vol. 1. Oxford, England: Oxford University Press, 1991:473-83.
13. Blom HJ, Ferenci P, Grimm G, Yap SH, Tangerman A. The role of methanethiol in the pathogenesis of hepatic encephalopathy. Hepatology 1991;13:445-54.
14. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-6.
15. Conn HO. The trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977;22:541-50.
16. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
17. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986;6:648-51.
18. Keays RT, Alexander GJ, Williams R. The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993; 18:205-9.
19. Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994;19:1407-13.
20. Bleichner G, Boulanger R, Squara P, Sollet JP, Parent A. Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage. Br J Surg 1986;73:724-6.
21. Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins, 1979.
22. Read AE, Laidlaw J, Sherlock S. Neuropsychiatrie complications of portacaval anastomosis. Lancet 1961;1:961-3.
23. Rössle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330:165-71.
24. Somberg KA, Riegler JL, LaBerge JM, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995;90:549-55.
25. Dagenais MH, Bernard D, Marleau D, et al. Surgical treatment of severe postshunt hepatic encephalopathy. World J Surg 1991;15:109-13.
26. Vavasseur D, Duvoux C, Cherqui D, et al. Chronic hepatic encephalopathy due to spontaneous splenorenal shunt: successful treatment by transhepatic shunt embolization. Cardiovasc Intervent Radiol 1994;17: 298-300.
27. Hauenstein KH, Haag K, Ochs A, Langer M, Rossle M. The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 1995;194: 175-9.
28. Baló J, Korpássy B. The encephalitis of dogs with Eck fistula fed on meat. Arch Pathol 1932;13:80-7.
29. Uribe M, Conn HO. Dietary management of portal-systemic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington, Ill.: Medi-Ed Press, 1994:331-49.
30. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy: a randomized cross-over comparison. J Intern Med 1993;233:385-92.
31. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double-blind controlled trial. Gastroenterology 1977;72:573-83.
32. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-43.
33. Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy: a meta-analysis. Dig Dis Sci 1993;38:916-22.
34. Blanc P, Daures JP, Rouillon JM, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992;15:222-8.
35. Uribe M, Marquez MA, Garcia-Ramos G, et al. Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients. Dig Dis Sci 1980;25:924-8.
36. Morgan MH, Read AE, Speller DCE. Treatment of hepatic encephalopathy with metronidazole. Gut 1982;23:1-7.
37. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis 1978;23:398-406.
38. Berk DP, Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med 1970;73:393-6.
39. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-18.
40. Weber FL Jr, Fresard KM, Lally BR. Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 1982;82: 213-7.
41. Weber FL Jr. Combination therapy with lactulose or lactitol and antibiotics. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington, Ill.: Medi-Ed Press, 1994:285-97.
42. Macbeth WAAG, Kass EH, McDermott WV Jr. Treatment of hepatic encephalopathy by alteration of intestinal flora and Lactobacillus acidophilus. Lancet 1965;1:399-403.
43. Read AE, McCarthy CF, Heaton KW, Laidlaw J. Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy. BMJ 1966;1: 1267-9.
44. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995;23:39-46.
45. Ito S, Miyaji H, Azuma T, et al. Hyperammonaemia and Helicobacter pylori. Lancet 1995;346:124-5.
46. Wiedmann B, Kircheis G, Klauk S, Günther L, Malfertheiner P. The influence of Helicobacter pylori (Hp) on protein-induced hyperammonemia (0.5 g/kg B.W.) in cirrhotic patients without hepatic encephalopathy. Hepatology 1996;24:Suppl:453A. abstract.
47. Kircheis G, Quack G, Erbler H. L-ornithine-L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington, Ill.: Medi-Ed Press, 1994:373-83.
48. Liehr H, Huth M, Kircheis G, Wagner M. A comparison of L-ornithine-L-aspartate and lactulose in the management of chronic liver disease and hepatic encephalopathy (HE). J Gastroenterol Hepatol 1992;7:Suppl 1:A106. abstract.
49. Chainuvati T, Plengvanit U, Viranuvatti V. Ornicetil on encephalopathy: effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease. Acta Hepatogastroenterol 1977;24:434-9.
50. Herlong HF, Maddrey WC, Walser M. The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy. Ann Intern Med 1980;93:545-50.
51. Mendenhall CL, Rouster S, Marshall L, Weesner R. A new therapy for portal systemic encephalopathy. Am J Gastroenterol 1986;81:540-3.
52. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992;16:138-44.
53. Keeling PWN, Jones RB, Hilton PJ, Thompson RPH. Reduced leucocyte zinc in liver disease. Gut 1980;21:561-4.
54. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100:1114-8.
55. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy: results of a randomised controlled trial. Lancet 1984;2:493-5.
56. Schölmerich J, Langenberger G, Steiert B, et al. Long term zinc substitution in patients with zinc deficiency in liver cirrhosis - results of a placebo controlled trial. Gastroenterology 1986;90:1765. abstract.
57. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy: results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-8.
58. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med 1993; 2:414-6.
59. Charlton MR. Branched chains revisited. Gastroenterology 1996;111: 252-5.
60. Fabbri A, Magrini N, Bianchi G, Zoli M, Marchesini G. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr 1996;20: 159-64.
61. Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984;4:279-87.
62. Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994;19:518-33.
63. Michel H, Solere M, Granier P, et al. Treatment of cirrhotic hepatic encephalopathy with L-dopa: a controlled trial. Gastroenterology 1980;79: 207-11.
64. Uribe M, Farca A, Marquez MA, Garcia-Ramos G, Guevara L. Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial. Gastroenterology 1979;76:1347-51.
65. Groeneweg M, Gyr K, Amrein R, et al. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy: results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalogr Clin Neurophysiol 1996;98:29-34.
66. Grimm G, Ferenci P, Katzenschlager R, et al. Improvement of hepatic encephalopathy treatment with flumazenil. Lancet 1988;2:1392-4.
67. Pomier-Layrargues G, Giguère JF, Lavoie J, et al. Efficacy of ro 15-1788 in cirrhotic patients with hepatic coma: results of a randomized double-blind placebo-controlled crossover trial. Hepatology 1992;16:Suppl: 122A. abstract.
68. Cotzias GC. Manganese in health and disease. Physiol Rev 1958;38: 503-32.
69. Pujol A, Pujol J, Graus F, et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993;43:65-9.
70. 1-weighted MRI in patients with liver failure. Neurology 1995;45:Suppl 4:A299. abstract.
71. Thuluvath PJ, Edwin D, Yue NC, de Villiers C, Hochman S, Klein A. Increased signals seen in globus pallidus in T1-weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy. Hepatology 1995;21:440-2.
72. Ky SQ, Deng HS, Xie PY, Hu W. A report of two cases of chronic serious manganese poisoning treated with sodium para-aminosalicylic acid. Br J Ind Med 1992;49:66-9.
73. Plauth M, Egberts EH, Hamster W, et al. Long-term treatment of latent portosystemic encephalopathy with branched chain amino acids: a double blind placebo-controlled crossover study. J Hepatol 1993;17:308-14.